The MDA-MB-157 breast cancer cell line is a triple negative cell line was derived from the pleural effusion metastasis of a 44 year old African American (79%) female previously diagnosed with ductal carcinoma of the breast. The cell line has been classified as a Basal B type based on molecular profiling. The STR profile along with other genomic data and information pertinent to this cell line can be found here at Cellosaurus, or here at COSMIC, or here at DepMap Portal.
Oncogene Signature: The Oncogene Signature of this triple negative breast cancer cell line has some noteworthy features. First, like most basal breast cancer cell lines, these cells have a common mutation in TP53 resulting in essentially no expression of this gene at the mRNA level. The cells also have a point mutation in the NF1 gene suggesting a role for signaling through RAS pathways. In these cells, both AURKA and CCNE1 are amplified, though not to a particularly high level, and both of these genes were hits in the CRISPR screen but not in the shRNA screen, although CCNE1 was close to the cut point. It is also noteworthy that FGFR1 is slightly amplified and overexpressed and was close to being a hit in the CRISPR screen, so this may be one cell line where FGFR1 plays a role in the growth/survival of the cells.
| Gene | CRISPR score | Demeter score | Log fold change | DNA amp | mutation | occ. In Cosmic |
| AURKA | -1.151492732 | -0.091530431 | 1.473330268 | 1.2691 | ||
| CCNE1 | -0.971734583 | -0.358326851 | 3.608878282 | 1.4946 | ||
| FGFR1 | -0.483580006 | -0.283649607 | 1.390525404 | 1.0728 | ||
| H3F3B | -0.387380459 | -0.211471858 | 1.215628884 | 1.1652 | ||
| GNA13 | -0.324900831 | 0 | 1.277828412 | 1.0419 | ||
| AXIN2 | -0.010064941 | 0.111627921 | 2.640839221 | 1.0419 | ||
| TP53 | 0.163629331 | -0.361268043 | -2.167164492 | 0.2759 | p.APSWPLSSS88fs | 99 |
| NF1 | 0.376841592 | -0.005831046 | 0.393782827 | -0.3572 | p.SEESLL2751fs | 8 |
MDA-157 Drug Sensitivities: This is one of those Basal B triple negative breast cancer cell lines that does not exhibit any significant drug sensitivities. There are no Tier 1 drugs because, even though FGFR1 is slightly amplified in these cells, they are not sensitive to any FGFR targeted drugs. There is one drug in the Tier 2 category that links drug sensitivity to gene essentiality for a gene that was barely a hit in the CRISPR screen but not a hit in the RNAi screen, so this is not a particularly exciting observation. Finally, no Tier 3 drugs were identified. Thus, this TP53, NF1 mutant Basal B breast cancer cell line exhibits no sensitivity to any targeted drugs.
| MDA-157T1 | |||||||||
| None | |||||||||
| MDA-157.T2 | |||||||||
| Drug name | Gene symbol_HGNC | z_score_GDSC1 | z_score_GDSC2 | DNA_amp | lfc | mutation | COSMIC_hit | achilles_score | demeter |
| OF-1 | BRPF1 | 0 | -1.934937 | 0.1937 | 0.682857031 | p.S36S | 0 | -0.572054752 | -0.105398379 |
| MDA-157.T3 | |||||||||
| None |
